Business
Pharma, WHO team up to create permanent ‘pandemic’ market for mandated, experimental vaccines
From LifeSiteNews
By Brenda Baletti, Ph.D., The Defender
Unlimited Hangout journalist Max Jones details how Big Pharma is using the WHO to restructure the drug market, so inadequately tested vaccines and other drugs will face minimal regulation and entire populations can be compelled to take them each time the WHO declares another global pandemic.
Big Pharma and its key investors are rolling out a new strategy — “the full takeover of the public sector, specifically the World Health Organization (WHO), and the regulatory system that now holds the entire market hostage” — according to a new investigative report by Unlimited Hangout’s Max Jones.
What’s behind the new strategy? The pharmaceutical industry is facing a “patent cliff” by 2030, as many of its blockbuster drugs are set to lose their patent protection, placing $180 billion in sales at risk and threatening to topple the industry.
According to Jones, for years, when patents expired on profitable drugs, pharmaceutical giants deployed a “mergers and acquisitions” strategy, buying up smaller drug companies to add to their product portfolios.
As a result, the industry is now dominated by a handful of companies, conventional chemical drugs exist for most health issues, and the regulatory process for new ones has become onerous.
Big Pharma has now pivoted to acquiring biotech and biologic companies, whose products are “more complex, unpredictable and difficult and expensive to make,” than chemical-based medicine, Jones wrote.
Conventional drugs are chemically synthesized and have a known structure according to the U.S. Food and Drug Administration (FDA). Biologics come from living humans, animal or microorganism cells, and are technologically altered to target particular proteins or cells in the immune system. The FDA calls biologics “complex mixtures that are not easily identified or characterized.”
As a drug class, biologics offer an appealing solution to the patent cliff problem, because they can’t be easily replicated like generic versions of conventional drugs.
Instead, producers make “biosimilars,” which unlike genetics can’t simply be interchanged with the original drug during a course of treatment without serious safety risks, according to Jones. And while generics are cheap, biosimilars are still expensive to produce. There also are regulatory hurdles to getting biosimilars to market.
However, Jones wrote, the serious safety issues associated with biologics — the high risk of serious adverse events associated with the COVID-19 vaccine, for example — make it difficult for drugmakers to find commercial success in a conventional regulatory environment.
“Luckily for Big Pharma,” Jones wrote, the WHO and its private backers “are pursuing an unprecedented legal process that would cement loopholes that could solve these significant market challenges of at least some biotechnologies.”
Such loopholes made Pfizer and Moderna’s COVID-19 mRNA vaccines — the paradigmatic example of this new strategy — Big Pharma’s highest-selling annual market success ever.
Distribution of the COVID-19 vaccines to approximately 70% of people globally was possible only because of the “fast-tracked, deregulated development and mandated consumption of the experimental drugs,” Jones wrote.
The industry hopes to replicate that model with other drugs. And it has already begun — last month the Biomedical Advanced Research and Development Authority, or BARDA, gave Moderna $176 million to develop an mRNA bird flu vaccine.
Stakeholders behind the WHO have turned it into an arm of Big Pharma
According to Jones, the process of rapidly developed and mandated experimental drugs was first adopted by the U.S. military for bioweapons threats. Now, it is being internationally legitimized by the WHO through the agency’s revisions to the International Health Regulations (IHR) and its continued attempt to push its pandemic treaty.
The amendments were watered down and the treaty was partially thwarted at the last meeting of the World Health Assembly, which ended on June 1. However, the powers added to the amendments and the language in the treaty WHO and its backers are still hoping to advance next year show the type of biotech pandemic market Big Pharma has in the works.
According to Jones, this market:
Will not be one that depends on the free will of consumers to opt in and out of products — but instead relies on tactics of forced consumption and manipulation of regulatory paradigms.
At the forefront of this push are the WHO’s public-private-partners/private stakeholders, who directly shape and benefit from this policy. Their influence has, in effect, turned the WHO into an arm of Big Pharma, one so powerful that it already demonstrated its ability to morph the entire international regulatory process for the benefit of the pharmaceutical industry during the COVID-19 pandemic.
These stakeholders can wield this power in part because the WHO receives 80% of its funding from private stakeholders.
Those stakeholders include private-sector giants like Bill Gates, his public-private partnership organizations like the Coalition for Epidemic Preparedness Innovations (CEPI) and public-sector bureaucrats, such as Dr. Anthony Fauci and Rick Bright, Ph.D., of BARDA and the Rockefeller Foundation, who have been working for years to create a new system that would speed up vaccine production.
During the COVID-19 pandemic period, even states that lacked legal structures to provide emergency authorization for new drugs created them, using the WHO’s Emergency Use Listing Procedure (EUL) as justification, and aided by the WHO’s COVAX vaccine distribution system. COVAX was co-led by the WHO, Gavi, CEPI and Unicef, which are all backed by Gates.
The goal now, Jones wrote, is to institutionalize the procedures that were put in place globally for COVID-19 to pave the way for a new pandemic market.
The One Health agenda, which requires “full-scale surveillance of the human-animal environment,” both before and during pandemics, is central to this plan, he wrote.
The four pillars of the emerging pandemic market
There are four pillars to the plan for securing this market. The pillars are embodied in the WHO’s recently passed IHR amendments and the proposed pandemic treaty.
1. Biosurveillance of “pathogens with pandemic potential”: The WHO is calling on member states to create infrastructure to conduct biosurveillance on entire populations.
WHO private stakeholders, like the Wellcome Trust and the Bill & Melinda Gates Foundation, have been funding such initiatives for years and continue to be at the forefront of similar initiatives today, Jones wrote.
2. Rapid sharing of data and research: Under the IHR amendments, the WHO’s director-general must provide support for member states’ research and development. In the pending treaty, that would include helping them rapidly share data during a pandemic.
Such sharing should help coordinate global pandemic responses and also “pandemic prevention.” That means building a globally coordinated effort to research and share data on diseases that don’t currently pose a public health threat but are allegedly “likely to cause epidemics in the future.”
The WHO’s announcement last week that it is facilitating data-sharing for a new mRNA bird flu vaccine from Argentina is one example.
Experts have raised concerns that incentivizing such “preventive R&D” could incentivize risky gain-of-function research, Jones wrote.
Jones also noted that it is “highly likely” that the same global organizations that partner with the WHO and are funded by its largest private donors will be the ones doing this research and development on vaccines for “future pathogens with pandemic potential” — and also the ones profiting from it.
3. New regulatory pathways: The WHO is developing new regulatory pathways for unapproved medical products to get to market during pandemic emergencies. The IHR amendments are vague on this, Jones wrote, but the proposed language of the treaty aims to speed up emergency authorizations of WHO-recommended investigational “relevant health products.”
The proposed treaty also seeks to compel member countries to take steps to ensure they have the “legal, administrative and financial frameworks in place to support emergency regulatory authorizations for the effective and timely approval of pandemic-related health products during a pandemic.”
4. Global mandates of unapproved products: The final key element in the Big Pharma-WHO plan to pave the way for a new pandemic market is shoring up the global capacity to mandate unapproved medical products.
According to Jones, in July 2023, the WHO adopted the European Union’s (EU) digital COVID-19 passport system, or the “immunity pass” which recorded people’s vaccination records, negative test results or records of previous infections.
“While a digital vaccine passport does not function as a hard mandate in which every citizen of a given population is forced to take a vaccine, it acts as a conditional mandate — one which offers the illusion of choice, but — in reality — restricts the civil liberties of those who do not comply,” Jones wrote.
The 2005 version of the IHR allowed for travel-based mandates that required proof of vaccination to enter countries when there was a public health risk. The new IHR, Jones wrote, expands on this by detailing the kinds of technology that can be used to check such information during future pandemics.
The WHO also is developing its Global Digital Health Certification Network, which expands the EU digital passport system to a global scale. It will digitize vaccination records and health records and will be “interoperable” with existing networks.
While interoperability makes it possible for decentralized data to be shared globally, Jones wrote, “The UN is seeking to impose digital identification as a ‘human right,’ or rather as a condition for accessing other human rights, for the entire global citizenry by 2030, as established in its Sustainable Development Goal 16.9.”
The initiative seeks to provide people with a “trusted, verifiable way” to prove who they are in the physical world and online.
Verification systems of this size will place the right of citizens to do basic activities — like traveling, eating at a restaurant or working their job — in the hands of governments and potentially employers.
The rights of civilians will be conditional, dictated by data stored in a massive digital hub that is global in its sharing abilities. Not only will domestic governments have access to the health information of their own citizens under this system, but an entire global bureaucracy will as well.
This article was originally published by The Defender — Children’s Health Defense’s News & Views Website under Creative Commons license CC BY-NC-ND 4.0. Please consider subscribing to The Defender or donating to Children’s Health Defense.
Alberta
Ford and Trudeau are playing checkers. Trump and Smith are playing chess
By Dan McTeague
Ford’s calls for national unity – “We need to stand united as Canadians!” – in context feels like an endorsement of fellow Electric Vehicle fanatic Trudeau. And you do wonder if that issue has something to do with it. After all, the two have worked together to pump billions in taxpayer dollars into the EV industry.
There’s no doubt about it: Donald Trump’s threat of a blanket 25% tariff on Canadian goods (to be established if the Canadian government fails to take sufficient action to combat drug trafficking and illegal crossings over our southern border) would be catastrophic for our nation’s economy. More than $3 billion in goods move between the U.S. and Canada on a daily basis. If enacted, the Trump tariff would likely result in a full-blown recession.
It falls upon Canada’s leaders to prevent that from happening. That’s why Justin Trudeau flew to Florida two weeks ago to point out to the president-elect that the trade relationship between our countries is mutually beneficial.
This is true, but Trudeau isn’t the best person to make that case to Trump, since he has been trashing the once and future president, and his supporters, both in public and private, for years. He did so again at an appearance just the other day, in which he implied that American voters were sexist for once again failing to elect the nation’s first female president, and said that Trump’s election amounted to an assault on women’s rights.
Consequently, the meeting with Trump didn’t go well.
But Trudeau isn’t Canada’s only politician, and in recent days we’ve seen some contrasting approaches to this serious matter from our provincial leaders.
First up was Doug Ford, who followed up a phone call with Trudeau earlier this week by saying that Canadians have to prepare for a trade war. “Folks, this is coming, it’s not ‘if,’ it is — it’s coming… and we need to be prepared.”
Ford said that he’s working with Liberal Finance Minister Chrystia Freeland to put together a retaliatory tariff list. Spokesmen for his government floated the idea of banning the LCBO from buying American alcohol, and restricting the export of critical minerals needed for electric vehicle batteries (I’m sure Trump is terrified about that last one).
But Ford’s most dramatic threat was his announcement that Ontario is prepared to shut down energy exports to the U.S., specifically to Michigan, New York, Wisconsin, and Minnesota, if Trump follows through with his plan. “We’re sending a message to the U.S. You come and attack Ontario, you attack the livelihoods of Ontario and Canadians, we’re going to use every tool in our toolbox to defend Ontarians and Canadians across the border,” Ford said.
Now, unfortunately, all of this chest-thumping rings hollow. Ontario does almost $500 billion per year in trade with the U.S., and the province’s supply chains are highly integrated with America’s. The idea of just cutting off the power, as if you could just flip a switch, is actually impossible. It’s a bluff, and Trump has already called him on it. When told about Ford’s threat by a reporter this week, Trump replied “That’s okay if he does that. That’s fine.”
And Ford’s calls for national unity – “We need to stand united as Canadians!” – in context feels like an endorsement of fellow Electric Vehicle fanatic Trudeau. And you do wonder if that issue has something to do with it. After all, the two have worked together to pump billions in taxpayer dollars into the EV industry. Just over the past year Ford and Trudeau have been seen side by side announcing their $5 billion commitment to Honda, or their $28.2 billion in subsidies for new Stellantis and Volkswagen electric vehicle battery plants.
Their assumption was that the U.S. would be a major market for Canadian EVs. Remember that “vehicles are the second largest Canadian export by value, at $51 billion in 2023 of which 93% was exported to the U.S.,”according to the Canadian Vehicle Manufacturers Association, and “Auto is Ontario’s top export at 28.9% of all exports (2023).”
But Trump ran on abolishing the Biden administration’s de facto EV mandate. Now that he’s back in the White House, the market for those EVs that Trudeau and Ford invested in so heavily is going to be much softer. Perhaps they’d like to be able to blame Trump’s tariffs for the coming downturn rather than their own misjudgment.
In any event, Ford’s tactic stands in stark contrast to the response from Alberta, Canada’s true energy superpower. Premier Danielle Smith made it clear that her province “will not support cutting off our Alberta energy exports to the U.S., nor will we support a tariff war with our largest trading partner and closest ally.”
Smith spoke about this topic at length at an event announcing a new $29-million border patrol team charged with combatting drug trafficking, at which said that Trudeau’s criticisms of the president-elect were, “not helpful.” Her deputy premier Mike Ellis was quoted as saying, “The concerns that president-elect Trump has expressed regarding fentanyl are, quite frankly, the same concerns that I and the premier have had.” Smith and Ellis also criticized Ottawa’s progressively lenient approach to drug crimes.
(For what it’s worth, a recent Léger poll found that “Just 29 per cent of [Canadians] believe Trump’s concerns about illegal immigration and drug trafficking from Canada to the U.S. are unwarranted.” Perhaps that’s why some recent polls have found that Trudeau is currently less popular in Canada than Trump at the moment.)
Smith said that Trudeau’s criticisms of the president-elect were, “not helpful.” And on X/Twitter she said, “Now is the time to… reach out to our friends and allies in the U.S. to remind them just how much Americans and Canadians mutually benefit from our trade relationship – and what we can do to grow that partnership further,” adding, “Tariffs just hurt Americans and Canadians on both sides of the border. Let’s make sure they don’t happen.”
This is exactly the right approach. Smith knows there is a lot at stake in this fight, and is not willing to step into the ring in a fight that Canada simply can’t win, and will cause a great deal of hardship for all involved along the way.
While Trudeau indulges in virtue signaling and Ford in sabre rattling, Danielle Smith is engaging in true statesmanship. That’s something that is in short supply in our country these days.
As I’ve written before, Trump is playing chess while Justin Trudeau and Doug Ford are playing checkers. They should take note of Smith’s strategy. Honey will attract more than vinegar, and if the long history of our two countries tell us anything, it’s that diplomacy is more effective than idle threats.
Dan McTeague is President of Canadians for Affordable Energy.
Business
Comparing four federal finance ministers in moments of crisis
From the Fraser Institute
By Grady Munro, Milagros Palacios and Jason Clemens
The sudden resignation of federal finance minister (and deputy prime minister) Chrystia Freeland, hours before the government was scheduled to release its fall economic update has thrown an already badly underperforming government into crisis. In her letter of resignation, Freeland criticized the government, and indirectly the prime minister, for “costly political gimmicks” and irresponsible handling of the country’s finances and economy during a period of great uncertainty.
But while Freeland’s criticism of recent poorly-designed federal policies is valid, her resignation, in some ways, tries to reshape her history into that of a more responsible finance minister. That is, however, ultimately an empirical question. If we contrast the performance of the last four long-serving (more than three years) federal finance ministers—Paul Martin (Liberal), Jim Flaherty (Conservative), Bill Morneau (Liberal) and Freeland (Liberal)—it’s clear that neither Freeland nor her predecessor (Morneau) were successful finance ministers in terms of imposing fiscal discipline or overseeing a strong Canadian economy.
Let’s first consider the most basic measure of economic performance, growth in per-person gross domestic product (GDP), adjusted for inflation. This is a broad measure of living standards that gauges the value of all goods and services produced in the economy adjusted for the population and inflation. The chart below shows the average annual growth in inflation-adjusted per-person GDP over the course of each finance minister’s term. (Adjustments are made to reflect the effects of temporary recessions or unique aspects of each minister’s tenure to make it easier to compare the performances of each finance minister.)
Sources: Statistics Canada Table 17-10-0005-01, Table 36-10-0222-01; 2024 Fall Economic Statement
By far Paul Martin oversaw the strongest growth in per-person GDP, with an average annual increase of 2.4 per cent. Over his entire tenure spanning a decade, living standards rose more than 25 per cent.
The average annual increase in per-person GDP under Flaherty was 0.6 per cent, although that includes the financial recession of 2008-09. If we adjust the data for the recession, average annual growth in per-person GDP was 1.4 per cent, still below Martin but more than double the rate if the effects of the recession are included.
During Bill Morneau’s term, average annual growth in per-person GDP was -0.5 per cent, although this includes the effects of the COVID recession. If we adjust to exclude 2020, Morneau averaged a 0.7 per cent annual increase—half the adjusted average annual growth rate under Flaherty.
Finally, Chrystia Freeland averaged annual growth in per-person GDP of -0.3 per cent during her tenure. And while the first 18 or so months of her time as finance minister, from the summer of 2020 through 2021, were affected by the COVID recession and the subsequent rebound, the average annual rate of per-person GDP growth was -0.2 per cent during her final three years. Consequently, at the time of her resignation from cabinet in 2024, Canadian living standards are projected to be 1.8 per cent lower than they were in 2019.
Let’s now consider some basic fiscal measures.
Martin is by far the strongest performing finance minister across almost every metric. Faced with a looming fiscal crisis brought about by decades of deficits and debt accumulation, he reduced spending both in nominal terms and as a share of the economy. For example, after adjusting for inflation, per-person spending on federal programs dropped by 5.9 per cent during his tenure as finance minister (see chart below). As a result, the federal government balanced the budget and lowered the national debt, ultimately freeing up resources via lower interest costs for personal and business tax relief that made the country more competitive and improved incentives for entrepreneurs, businessowners, investors and workers.
*Note: Freeland’s term began in 2020, but given the influence of COVID, 2019 is utilized as the baseline for the overall change in spending. Sources: Statistics Canada Table 17-10-0005-01, Table 36-10-0130-01; Fiscal Reference Tables 2024; 2024 Fall Economic Statement
Flaherty’s record as finance minister is mixed, in part due to the recession of 2008-09. Per-person program spending (inflation adjusted) increased by 11.6 per cent, and there was a slight (0.6 percentage point) increase in spending as a share of the economy. Debt also increased as a share of the economy, although again, much of the borrowing during Flaherty’s tenure was linked with the 2008-09 recession. Flaherty did implement tax relief, including extending the business income tax cuts started under Martin, which made Canada more competitive in attracting investment and fostering entrepreneurship.
Both Morneau and Freeland recorded much worse financial performances than Flaherty and Martin. Morneau increased per-person spending on programs (inflation adjusted) by 37.1 per cent after removing 2020 COVID-related expenditures. Even if a more generous assessment is used, specifically comparing spending in 2019 (prior to the effects of the pandemic and recession) per-person spending still increased by 18.1 per cent compared to the beginning of his tenure.
In his five years, Morneau oversaw an increase in total federal debt of more than $575 billion, some of which was linked with COVID spending in 2020. However, as multiple analyses have concluded, the Trudeau government spent more and accumulated more debt during COVID than most comparable industrialized countries, with little or nothing to show for it in terms of economic growth or better health performance. Simply put, had Morneau exercised more restraint, Canada would have accumulated less debt and likely performed better economically.
Freeland’s tenure as finance minister is the shortest of the four ministers examined. It’s nonetheless equally as unimpressive as that of her Trudeau government predecessor (Morneau). If we use baseline spending from 2019 to adjust for the spike in spending in 2020 when she was appointed finance minister, per-person spending on programs by the federal government (inflation adjusted) during Freeland’s term increased by 4.1 per cent. Total federal debt is expected to increase from $1.68 trillion when Freeland took over to an estimated $2.2 trillion this year, despite the absence of a recession or any other event that would impair federal finances since the end of COVID in 2021. For some perspective, the $470.8 billion in debt accumulated under Freeland is more than double the $220.3 billion accumulated under Morneau prior to COVID. And there’s an immediate cost to that debt in the form of $53.7 billion in expected federal debt interest costs this year. These are taxpayer resources unavailable for actual services such as health care.
Freeland’s resignation from cabinet sent shock waves throughout the country, perhaps relieving her of responsibility for the Trudeau government’s latest poorly-designed fiscal policies. However, cabinet ministers bear responsibility for the performance of their ministries—meaning Freeland must be held accountable for her previous budgets and the fiscal and economic performance of the government during her tenure. Compared to previous long-serving finances ministers, it’s clear that Chrystia Freeland, and her Trudeau predecessor Bill Morneau, failed to shepherd a strong economy or maintain responsible and prudent finances.
-
Alberta19 hours ago
Proposed $70 billion AI data centre in MD of Greenview could launch an incredible new chapter for western Canadian energy
-
COVID-192 days ago
Australian doctor who criticized COVID jabs has his suspension reversed
-
Business2 days ago
Massive growth in federal workforce contributes to Ottawa’s red ink
-
Alberta15 hours ago
Your towing rights! AMA unveils measures to help fight predatory towing
-
Frontier Centre for Public Policy2 days ago
False Claims, Real Consequences: The ICC Referrals That Damaged Canada’s Reputation
-
COVID-192 days ago
Former Trudeau minister faces censure for ‘deliberately lying’ about Emergencies Act invocation
-
National2 days ago
When’s the election? Singh finally commits. Poilievre asks Governor General to step in
-
Business2 days ago
Senator Introduces Bill To Send One-Third Of Federal Workforce Packing Out Of DC